Ironwood eyes China for IBS drug

Cambridge-based Ironwood Pharmaceuticals Inc. is reporting promising clinical trial data about its irritable bowel syndrome drug developed with AstraZeneca, news that has prompted the companies to look at Chinese regulatory approval. Data coming out of the trial indicates that the drug, known as linaclotide, significantly improved several areas of irritable bowel syndrome-constipation, including abdominal pain, bloating, and frequency of bowel movements. The most common adverse side effect was diarrhea. The…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news